TABLE 1

Basic characteristics of experimental groups after 4-week treatment with vehicle (VEH), pioglitazone (PIO), or glibenclamide (GLIB)

LETO-VEHLETO-PIOLETO-GLIBOLETF-VEHOLETF-PIOOLETF-GLIBP value
n141212141212
Body weight (g)339.8 ± 4.6346.4 ± 6.0357.6 ± 6.9383.4 ± 5.3*377.6 ± 7.7*423.5 ± 4.7*§<0.001
LV weight (g)0.91 ± 0.020.88 ± 0.030.96 ± 0.051.03 ± 0.02*1.16 ± 0.31*1.15 ± 0.03*§<0.001
LV/body weight (mg/g)2.58 ± 0.062.52 ± 0.092.73 ± 0.192.59 ± 0.052.81 ± 0.152.73 ± 0.06NS
Plasma glucose (mmol/l)5.02 ± 0.165.08 ± 0.295.08 ± 0.295.14 ± 0.384.44 ± 0.214.93 ± 0.25NS
Plasma insulin (ng/ml)1.94 ± 0.531.72 ± 0.503.32 ± 0.605.24 ± 1.19*2.69 ± 0.514.79 ± 0.87<0.01
Total cholesterol (mg/dl)75.2 ± 1.673.9 ± 4.571.8 ± 3.073.5 ± 3.072.1 ± 5.172.0 ± 6.2NS
Triglycerides (mg/dl)32.9 ± 3.830.2 ± 2.236.0 ± 4.561.1 ± 6.2*54.2 ± 2.5*62.9 ± 6.1*<0.001
Free fatty acid (mg/dl)397.4 ± 21.9348.2 ± 34.0381.1 ± 31.0639.5 ± 73.9606.4 ± 61.2*724.0 ± 53.0*<0.001
  • Data are means ± SE.

  • *

    * P < 0.01,

  • P < 0.05 vs. corresponding LETO groups;

  • P < 0.05,

  • §

    § P < 0.01 vs. corresponding vehicle-treated groups. LV, left ventricle.